For this article:

6 Feb 2026·Source: The Hindu
4 min
EconomyInternational RelationsSocial IssuesNEWS

MSF Raises Concerns Over FTA Impact on Medicines in India

MSF warns EU-India Free Trade Agreement could restrict medicine access.

Médecins Sans Frontières (MSF) has expressed concern to the European Union that the EU-India Free Trade Agreement could restrict access to medicines in India and the developing world. MSF warns that the agreement may strengthen the monopoly rights of multinational pharmaceutical manufacturers, potentially blocking compulsory licenses, patent term extensions, and generic competition.

They specifically expressed concern over data exclusivity and border measures that seek to detain imports or exports of goods suspected of infringing intellectual property rights. MSF says generic competition is key to lowering medicine prices.

Key Facts

1.

Médecins Sans Frontières (MSF) has expressed concern to the European Union about the EU-India Free Trade Agreement.

2.

MSF warns that the agreement may strengthen the monopoly rights of multinational pharmaceutical manufacturers.

3.

The agreement could potentially block compulsory licenses, patent term extensions, and generic competition.

4.

MSF specifically expressed concern over data exclusivity and border measures.

UPSC Exam Angles

1.

GS Paper II: International Agreements and their impact on India

2.

GS Paper III: Intellectual Property Rights

3.

Potential for questions on international trade and health policy

Visual Insights

Countries Involved in EU-India FTA Negotiations

This map highlights India and the European Union, the two major parties involved in the Free Trade Agreement negotiations. It shows the potential impact area of the agreement and the geographical context of the concerns raised by MSF.

Loading interactive map...

📍India📍European Union
More Information

Background

The issue of access to medicines and intellectual property rights has a long history, particularly concerning developing countries. The TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights) administered by the World Trade Organization (WTO), established minimum standards for intellectual property regulation. However, concerns arose that these standards could limit access to affordable medicines in developing nations. In response to these concerns, the Doha Declaration on the TRIPS Agreement and Public Health in 2001 affirmed the right of WTO member states to use the flexibilities within the TRIPS Agreement to address public health crises. These flexibilities include the use of compulsory licensing, which allows governments to authorize the production of generic versions of patented medicines without the patent holder's consent, under certain conditions. This declaration was crucial in ensuring access to essential medicines, particularly for diseases like HIV/AIDS. India's patent law, specifically the Patents Act of 1970, includes provisions that support generic drug manufacturing and promote access to medicines. Section 3(d) of the Act prevents the patenting of new forms of known substances unless they demonstrate significantly enhanced efficacy. This provision has been instrumental in preventing evergreening, a practice where pharmaceutical companies extend patent protection by making minor modifications to existing drugs. The Act also allows for compulsory licensing under specific circumstances, balancing intellectual property rights with public health needs.

Latest Developments

The ongoing negotiations for the EU-India Free Trade Agreement have raised concerns about the potential impact on access to medicines. The EU is pushing for stronger intellectual property protections, including data exclusivity and stricter border measures. These measures could delay the entry of generic medicines into the market, potentially increasing healthcare costs.

Civil society organizations, like Médecins Sans Frontières (MSF), are actively advocating for the inclusion of safeguards in the FTA to protect access to affordable medicines. They argue that the agreement should not undermine India's ability to produce and export generic drugs, which are crucial for treating diseases in developing countries. MSF's concerns highlight the tension between promoting innovation through intellectual property rights and ensuring access to essential medicines for all.

The Indian government faces the challenge of balancing its commitment to protecting intellectual property rights with its responsibility to ensure affordable healthcare for its citizens. The outcome of the FTA negotiations will have significant implications for the future of generic drug manufacturing in India and access to medicines in the developing world. The government will need to carefully consider the potential impact of the agreement on public health and ensure that adequate safeguards are in place.

Frequently Asked Questions

1. What are the key facts from the MSF concerns about the EU-India FTA that are important for the UPSC Prelims exam?

For UPSC Prelims, remember that Médecins Sans Frontières (MSF) is concerned the EU-India Free Trade Agreement (FTA) could restrict access to medicines in India. MSF fears the FTA may strengthen the monopoly rights of multinational pharmaceutical manufacturers, potentially blocking compulsory licenses, patent term extensions, and generic competition. Also, remember their concerns over data exclusivity and border measures.

2. What is the potential impact of the EU-India FTA on access to medicines, according to MSF?

MSF warns that the EU-India FTA could restrict access to medicines in India and the developing world. They are concerned that the agreement may strengthen the monopoly rights of multinational pharmaceutical manufacturers. This could block compulsory licenses, patent term extensions, and generic competition, ultimately leading to higher medicine prices.

3. What are 'compulsory licenses' and why is MSF concerned about them in the context of the EU-India FTA?

Compulsory licenses allow governments to authorize generic production of patented medicines under certain conditions, even without the patent holder's consent. MSF is concerned that the EU-India FTA might include provisions that make it harder for India to issue compulsory licenses, thus limiting access to affordable generic medicines.

4. Why is the EU-India Free Trade Agreement in the news recently?

The EU-India Free Trade Agreement is in the news because negotiations are ongoing, and concerns have been raised by Médecins Sans Frontières (MSF) regarding its potential impact on access to medicines. MSF has expressed these concerns to the European Union.

5. What are the pros and cons of stronger intellectual property rights for pharmaceutical companies, considering the MSF's concerns about the EU-India FTA?

Pros include incentivizing innovation and investment in new medicines. Cons include potentially limiting access to affordable medicines, especially in developing countries, by extending monopolies and hindering generic competition. MSF argues the cons outweigh the pros in this case.

6. What are 'data exclusivity' and 'border measures' and why are they a concern in the context of the EU-India FTA and access to medicines?

Data exclusivity prevents generic manufacturers from relying on the originator's clinical trial data for a certain period, delaying generic entry. Border measures allow customs officials to detain imports or exports suspected of infringing intellectual property rights. MSF is concerned these measures could be used to block legitimate generic medicines.

Practice Questions (MCQs)

1. Consider the following statements regarding the TRIPS Agreement: 1. The TRIPS Agreement is administered by the World Health Organization (WHO). 2. The TRIPS Agreement establishes minimum standards for intellectual property regulation. 3. The Doha Declaration on the TRIPS Agreement and Public Health reaffirmed the right of WTO member states to use flexibilities within the TRIPS Agreement to address public health crises. Which of the statements given above is/are correct?

  • A.1 and 2 only
  • B.2 and 3 only
  • C.1 and 3 only
  • D.1, 2 and 3
Show Answer

Answer: B

Statement 1 is INCORRECT: The TRIPS Agreement is administered by the World Trade Organization (WTO), not the World Health Organization (WHO). Statement 2 is CORRECT: The TRIPS Agreement establishes minimum standards for intellectual property regulation. Statement 3 is CORRECT: The Doha Declaration on the TRIPS Agreement and Public Health reaffirmed the right of WTO member states to use flexibilities within the TRIPS Agreement to address public health crises. This includes the use of compulsory licensing.

2. In the context of access to medicines, what does 'compulsory licensing' refer to?

  • A.A requirement for pharmaceutical companies to disclose their research data.
  • B.A government's authorization to produce generic versions of patented medicines without the patent holder's consent.
  • C.A voluntary agreement between pharmaceutical companies to lower drug prices.
  • D.A system where governments directly purchase medicines from pharmaceutical companies at negotiated prices.
Show Answer

Answer: B

Compulsory licensing refers to a government's authorization to produce generic versions of patented medicines without the patent holder's consent, usually under specific circumstances such as a public health crisis. This is a flexibility allowed under the TRIPS Agreement.

3. Which of the following provisions in India's Patents Act of 1970 is aimed at preventing 'evergreening' of patents?

  • A.Section 3(a)
  • B.Section 3(b)
  • C.Section 3(d)
  • D.Section 3(f)
Show Answer

Answer: C

Section 3(d) of the Patents Act of 1970 prevents the patenting of new forms of known substances unless they demonstrate significantly enhanced efficacy. This provision is aimed at preventing 'evergreening,' a practice where pharmaceutical companies extend patent protection by making minor modifications to existing drugs.

Source Articles

Concerned that FTA may cut access to medicines in India, rest of the developing world: Médecins Sans Frontières writes to EU - The Hindu

The Hindu·6 Feb 2026

Kanimozhi Somu urges government to halt online medicine delivery - The Hindu

The Hindu·6 Feb 2026

India’s drug safety deficit: critical gaps in an overly complex system need urgent remedies - The Hindu

The Hindu·6 Feb 2026

Committees on medicines, devices should continue till COVID-19 is over: report - The Hindu

The Hindu·6 Feb 2026

Weak regulation causing deaths due to contaminated medicines, WHO says - The Hindu

The Hindu·6 Feb 2026

GKSolverToday's News